



UNIVERSITY OF LEEDS

This is a repository copy of *Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/109312/>

Version: Supplemental Material

---

**Article:**

Bell, R, Brown, JM [orcid.org/0000-0002-2719-7064](http://orcid.org/0000-0002-2719-7064), Parmar, M et al. (18 more authors) (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Annals of Oncology*, 28 (4). pp. 754-760. ISSN 0923-7534

<https://doi.org/10.1093/annonc/mdw665>

---

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. This is a pre-copyedited, author-produced PDF of an article accepted for publication in *Annals of Oncology* following peer review. The version of record, 'Bell, R, Brown, JM, Parmar, M et al (2017) Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Annals of Oncology*, 28 (4). pp. 754-760,' doi: 10.1093/annonc/mdw665; is available online at: <https://doi.org/10.1093/annonc/mdw665>.

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Supplementary Table S2.** Causes of death other than breast cancer recurrence  
(safety population, N = 2559)

Cause of death, no. of patients	Chemotherapy alone (N = 1271)	Chemotherapy + bevacizumab (N = 1288)
Total	16	8
Cardiac failure	1	0
Coronary artery disease	0	1
Cerebral hemorrhage	1	0
Cerebrovascular accident	0	1
Hypoxic-ischemic encephalopathy	1	0
Sepsis	0	1
Neutropenic sepsis	1	0
Septic shock	1	0
Shock	1	0
Varicella zoster pneumonia	1	0
Multi-organ failure	0	1

---

Death (not otherwise specified)	1	1
Metastasis <sup>a</sup>	1	0
Brain neoplasm	1	0
Metastatic malignant melanoma	2	0
Pancreatic carcinoma	2	0
Acute myeloid leukemia	0	1
Bronchial carcinoma	0	1
Gastric cancer	0	1
Lung neoplasm malignant	1	0
Pancreatic carcinoma metastatic	1	0

---

<sup>a</sup>Not confirmed as metastatic breast cancer.

---